Blog
RSS FeedPosted by Michael Wonder on 19 Apr 2024
National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...
Posted by Michael Wonder on 12 Apr 2024
Waiting for new medicines in Canada, Europe, and the United States: study finds Americans get better and faster access to innovative drugs
11 April 2024 - A recent study published by the Canadian Health Policy Institute examined the availability and wait times ...
Posted by Michael Wonder on 10 Apr 2024
New target zero initiative aims to help improve access to new drugs
9 April 2024 - Target Zero is a new initiative that aims to improve the time to access for patients ...
Posted by Michael Wonder on 06 Apr 2024
Nurtec ODT is now available in Canada for the treatment of acute migraine
4 April 2024 - More than one billion people worldwide live with migraine, and the World Health Organization classifies migraine ...
Posted by Michael Wonder on 05 Apr 2024
Bausch Health Canada announces first public drug plan listings for Uceris (budesonide) aerosol foam to help address the unmet need for the treatment of mild to moderate distal ulcerative colitis in adults
3 April 2024 - Bausch Health Canada today announced the first public drug plan listings for Uceris (budesonide) aerosol foam ...
Posted by Michael Wonder on 04 Apr 2024
New model validation tool to support economic evaluations of health technologies
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
Posted by Michael Wonder on 02 Apr 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat oral solution) receives positive reimbursement recommendation by Canada’s CADTH for patients with cholestatic pruritus in Alagille syndrome
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with ...
Posted by Michael Wonder on 05 Mar 2024
Nine drug formularies in Canada list Evenity for reimbursement for the treatment of osteoporosis in post-menopausal women as high risk of fracture
5 March 2024 - Multiple formulary listings are a step forward to ensuring that post-menopausal women have access to medicines ...
Posted by Michael Wonder on 04 Mar 2024
Findings from the Lean review of our drug reimbursement review program
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
Posted by Michael Wonder on 29 Feb 2024
Collaborating to help improve access to drugs for rare diseases
29 February 2024 - On Rare Disease Day — a day when the international community raises awareness about rare conditions ...
Posted by Michael Wonder on 24 Feb 2024
Drug insurance: a single payer pharmacare program would jeopardise coverage quality for 21 million Canadians
22 February 2024 - Imposing a single payer universal drug insurance plan on all Canadians would jeopardise coverage quality for ...
Posted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 08 Feb 2024
HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 18 Jan 2024
Sudbury, Ontario family finally gets coverage for drug to treat daughter's rare epilepsy
16 January 2024 - Fenfluramine costs more than $3,000 a month and is not approved by Health Canada. ...